The clinical applications of curcumin: Current state and the future

Current Pharmaceutical Design

Volumn 19, Issue 11, 2013, Pages 2011-2031

  Fan, Xia ^a   Zhang, Chun ^a   Liu, Dong Bo ^a   Yan, Jun ^a   Liang, Hua ping ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Bioavailability; Cancer; Clinical application; Curcumin; Inflammation

Indexed keywords

ANTINEOPLASTIC AGENT; BIOPERINE; C3 COMPLEX; CAPECITABINE; CURCUMIN; DEMETHOXYCURCUMIN; DICLOFENAC; DIDEMETHOXYCURCUMIN; DOCETAXEL; ESTRADIOL VALERATE; FLUOROURACIL; FOLINIC ACID; GINKGO BILOBA EXTRACT; MESALAZINE; OXALIPLATIN; PHENYLBUTAZONE; PIPERINE; PLACEBO; SALAZOSULFAPYRIDINE; UNCLASSIFIED DRUG;

ALLERGIC ASTHMA; ALZHEIMER DISEASE; ANTIANGIOGENIC ACTIVITY; ANTIFUNGAL ACTIVITY; ANTIMICROBIAL ACTIVITY; ANTIOXIDANT ACTIVITY; ANTIVIRAL ACTIVITY; APOPTOSIS; ARTHROPATHY; ARTICLE; BIOLOGICAL ACTIVITY; BREAST CANCER; CANCER PREVENTION; CARDIOVASCULAR DISEASE; CELL ADHESION; CELL MOTILITY; CELL PROLIFERATION; CEREBROVASCULAR ACCIDENT; COLON CANCER; COLON CARCINOMA; COLORECTAL CANCER; CURCUMA LONGA; DIABETES MELLITUS; DIARRHEA; DIET SUPPLEMENTATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; ENTERITIS; EYE DISEASE; FAMILIAL COLON POLYPOSIS; GASTROINTESTINAL SYMPTOM; HEAD AND NECK CANCER; HEADACHE; HIGH RISK PATIENT; HUMAN; HYPERPROLACTINOMA; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY DISEASE; IRRITABLE COLON; KNEE OSTEOARTHRITIS; LIVER METASTASIS; MAXIMUM PLASMA CONCENTRATION; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEOPLASM; NONHUMAN; ORAL MUCOSITIS; ORBIT PSEUDOTUMOR; OSTEOSARCOMA; PANCREAS CANCER; PANCREATITIS; PARASITEMIA; PARKINSON DISEASE; PEPTIC ULCER; PNEUMONIA; POLYPOSIS; PRIORITY JOURNAL; PROLACTINOMA; PSORIASIS; RADIATION PROTECTION; RECTUM CANCER; RETINA MACULA EDEMA; RHEUMATOID ARTHRITIS; STOMACH ULCER; T CELL LYMPHOMA; TIME TO MAXIMUM PLASMA CONCENTRATION; ULCERATIVE COLITIS; UVEITIS; VITRITIS;

EID: 84875388603     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161213805289255     Document Type: Article

References (232)

1. Balunas MJ, Kinghorn AD. Drug discovery from medicinal plants. Life Sci 2005; 78: 431-41.
2. Butler MS. The role of natural product chemistry in drug discovery. J Nat Prod 2004; 67: 2141-53.
3. Gurib-Fakim A. Medicinal plants: traditions of yesterday and drugs of tomorrow. Mol Asp Med 2006; 27: 1-93.
4. Newman DJ, Cragg GM. Natural Products as Sources of New Drugs over the Last 25 Years. J Nat Prod 2007; 70: 461-77.
5. Newman DJ, Cragg GM, Snader KM. Natural products as sources of new drugs over the period 1981-2002. J Nat Prod 2003; 66: 1022-37.
6. Mukherjee PK, Wahile A. Integrated approaches towards drug development from Ayurveda and other Indian system of medicines. J Ethnopharmacol 2006; 103: 25-35.
7. Ammon H, Wahl MA. Pharmacology of Curcuma longa. Planta Med 1991; 57: 1-7.
8. Aggarwal BB, Sundaram C, Malani N, Ichikawa H. Curcumin: the Indian solid gold. Adv Exp Med Biol 2007; 595: 1-75.
9. Goel A, Kunnumakkara AB, Aggarwal BB. Curcumin as "Curecumin": From kitchen to clinic. Biochem Pharmacol 2008; 75: 787-809.
10. Kiuchi F, Goto Y, Sugimoto N, Akao N, Kondo K, Tsuda Y. Nematocidal activity of turmeric: synergistic action of curcuminoids. Chem pharm bull 1993; 41: 1640.
11. Hatcher H, Planalp R, Cho J, Torti FM, Torti SV. Curcumin: from ancient medicine to current clinical trials. Cell Mol Life Sci 2008; 65: 1631-52.
12. Tilak JC, Banerjee M, Mohan H, Devasagayam T. Antioxidant availability of turmeric in relation to its medicinal and culinary uses. Phytother Res 2004; 18: 798-804.
13. Shishodia S, Sethi G, Aggarwal BB. Curcumin: getting back to the roots. Ann N Y Acad Sci 2005; 1056: 206-17.
14. Alexander RW. Hypertension and the pathogenesis of atherosclerosis-oxidative stress and the mediation of arterial inflammatory response-a new perspective. Hypertension 1995; 25: 155-61.
15. Keaney JF, Vita JA. Atherosclerosis, oxidative stress, and antioxidant protection in endothelium-derived relaxing factor action. Prog Cardiovasc Dis 1995; 38: 129-54.
16. Harrison D, Griendling KK, Landmesser U, Hornig B, Drexler H. Role of oxidative stress in atherosclerosis. Am J Cardiol 2003; 91: 7A-11A.
17. Das DK, Maulik N, Moraru, II. Gene-expression in acute myocardial stress-induction by hypoxia, ischemia, reperfusion, hyperthermia and oxidative stress. J Mol Cell Cardiol 1995; 27: 181-93.
18. Ferrari R, Guardigli G, Mele D, Percoco GF, Ceconi C, Curello S. Oxidative stress during myocardial ischaemia and heart failure. Curr Pharm Des 2004; 10: 1699-711.
19. Yoshizumi M, Tsuchiya K, Tamaki T. Signal transduction of reactive oxygen species and mitogen-activated protein kinases in cardiovascular disease. J Med Investig 2001; 48: 11-24.
20. Takano H, Zou YZ, Hasegawa H, Akazawa H, Nagai T, Komuro I. Oxidative stress-induced signal transduction pathways in cardiac myocytes: Involvement of ROS in heart diseases. Antioxid Redox Signal 2003; 5: 789-94.
21. Joe B, Lokesh B. Role of capsaicin, curcumin and dietary-N-3 fatty acids in lowering the generation of reactive oxygen species in rat peritoneal macrophages. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research 1994; 1224: 255-63.
22. Motterlini R, Foresti R, Bassi R, Green CJ. Curcumin, an antioxidant and anti-inflammatory agent, induces heme oxygenase-1 and protects endothelial cells against oxidative stress. Free Radic Biol Med 2000; 28: 1303-12.
23. Hill-Kapturczak N, Thamilselvan V, Liu FY, Nick HS, Agarwal A. Mechanism of heme oxygenase-1 gene induction by curcumin in human renal proximal tubule cells. Am J Physiol Renal Physiol 2001; 281: F851-F9.
24. McNally SJ, Harrison EM, Ross JA, Garden OJ, Wigmore SJ. Curcumin induces heme oxygenase 1 through generation of reactive oxygen species, p38 activation and phosphatase inhibition. Int J Mol Med 2007; 19: 165-72.
25. Kunwar A, Simon E, Singh U, et al. Interaction of a curcumin analogue dimethoxycurcumin with DNA. Chem Biol Drug Des 2011; 77: 281-7.
26. Murphy EA, Davis JM, McClellan JL, Gordon BT, Carmichael MD. Curcumin's Effect on Intestinal Inflammation and Tumorigenesis in the Apc Min/+ Mouse. J Interferon Cytokine Res 2011; 31: 219-26.
27. Moragoda L, Jaszewski R, Majumdar APN. Curcumin induced modulation of cell cycle and apoptosis in gastric and colon cancer cells. Anticancer Res 2001; 21: 873-8.
28. Woo JH, Kim YH, Choi YJ, et al. Molecular mechanisms of curcumin-induced cytotoxicity: induction of apoptosis through generation of reactive oxygen species, down-regulation of Bcl-X-L and IAP, the release of cytochrome c and inhibition of Akt. Carcinogenesis 2003; 24: 1199-208.
29. Pan MH, Chang WL, Lin-Shiau SY, Ho CT, Lin JK. Induction of apoptosis by garcinol and curcumin through cytochrome c release and activation of caspases in human leukemia HL-60 cells. J Agric Food Chem 2001; 49: 1464-74.
30. Lin S-S, Huang H-P, Yang J-S, et al. DNA damage and endoplasmic reticulum stress mediated curcumin-induced cell cycle arrest and apoptosis in human lung carcinoma A-549 cells through the activation caspases cascade-and mitochondrial-dependent pathway. Cancer Lett 2008; 272: 77-90.
31. Singh S, Aggarwal BB. Activation of transcription factor NF-κB is suppressed by curcumin (diferuloylmethane). J Biol Chem 1995; 270: 24995-5000.
32. Stephens L, Anderson K, Stokoe D, et al. Protein kinase B kinases that mediate phosphatidylinositol 3, 4, 5-trisphosphate-dependent activation of protein kinase B. Science 1998; 279: 710-4.
33. Woo JH, Kim YH, Choi YJ, et al. Molecular mechanisms of curcumin-induced cytotoxicity: induction of apoptosis through generation of reactive oxygen species, down-regulation of Bcl-XL and IAP, the release of cytochrome c and inhibition of Akt. Carcinogenesis 2003; 24: 1199-208.
34. Jee SH, Shen SC, Tseng CR, Chiu HC, Kuo ML. Curcumin induces a p53-dependent apoptosis in human basal cell carcinoma cells. J Investig Dermatol 1998; 111: 656-61.
35. Tharakan ST, Inamoto T, Sung B, Aggarwal BB, Kamat AM. Curcumin potentiates the antitumor effects of gemcitabine in an orthotopic model of human bladder cancer through suppression of proliferative and angiogenic biomarkers. Biochem Pharmacol 2010; 79: 218-28.
36. Rashmi R, Kumar S, Karunagaran D. Human colon cancer cells lacking Bax resist curcumin-induced apoptosis and Bax requirement is dispensable with ectopic expression of Smac or downregulation of Bcl-XL. Carcinogenesis 2005; 26: 713-23.
37. Chakraborty S, Ghosh U, Bhattacharyya N, Bhattacharya R, Roy M. Inhibition of telomerase activity and induction of apoptosis by curcumin in K-562 cells. Mutat Res-Fund Mol M 2006; 596: 81-90.
38. Su CC, Lin JG, Li Temao, et al. Curcumin-induced apoptosis of human colon cancer colo 205 cells through the production of ROS, Ca2+ and the activation of caspase-3. Anticancer Res 2006; 26: 4379-89.
39. Simon A, Allais D, Duroux J, Basly J, Durand-Fontanier S, Delage C. Inhibitory effect of curcuminoids on MCF-7 cell proliferation and structure-activity relationships. Cancer Lett 1998; 129: 111-6.
40. Mukhopadhyay A, Banerjee S, Stafford LJ, Xia C, Liu M, Aggarwal BB. Curcumin-induced suppression of cell proliferation correlates with down-regulation of cyclin D1 expression and CDK4-mediated retinoblastoma protein phosphorylation. Oncogene 2002; 21: 8852-61.
41. Shao H, Tan Y, Eton D, et al. Statin and Stromal Cell-Derived Factor-1 Additively Promote Angiogenesis by Enhancement of Progenitor Cells Incorporation into New Vessels. Stem cells 2008; 26: 1376-84.
42. Pae H-O, Jeong S-O, Kim HS, et al. Dimethoxycurcumin, a synthetic curcumin analogue with higher metabolic stabillity, inhibits NO production, inducible NO synthase expression and NFkappa B activation in RAW264.7 macrophages activated with LPS. Mol Nutr Food Res 2008; 52: 1082-91.
43. Ramachandran C, Fonseca HB, Jhabvala P, Escalon EA, Melnick SJ. Curcumin inhibits telomerase activity through human telomerase reverse transcritpase in MCF-7 breast cancer cell line. Cancer Lett 2002; 184: 1-6.
44. Cui S-X, Qu X-J, Xie Y-Y, et al. Curcumin inhibits telomerase activity in human cancer cell lines. Int J Mol Med 2006; 18: 227-31.
45. Mukherjee S, Ghosh U, Bhattacharyya NP, Bhattacharya RK, Dey S, Roy M. Curcumin-induced apoptosis in human leukemia cell HL-60 is associated with inhibition of telomerase activity. Mol Cell Biochem 2007; 297: 31-9.
46. Mishra VK, Kumar A. Curcumin induced cell death and inhibition of telomerase activity in mouse lymphoma p388d1 cells. Excli Journal 2009; 8: 20-9.
47. Lee JH, Chung IK. Curcumin inhibits nuclear localization of telomerase by dissociating the Hsp90 co-chaperone p23 from hTERT. Cancer Lett 2010; 290: 76-86.
48. Jaiswal AS, Marlow BP, Gupta N, Narayan S. beta-Catenin-mediated transactivation and cell-cell adhesion pathways are important in curcumin (diferuylmethane)-induced growth arrest and apoptosis in colon cancer cells. Oncogene 2002; 21: 8414-27.
49. Narayan S. Curcumin, a multi-functional chemopreventive agent, blocks growth of colon cancer cells by targeting beta-cateninmediated transactivation and cell-cell adhesion pathways. J Mol Hist 2004; 35: 301-7.
50. Ray S, Chattopadhyay N, Mitra A, Siddiqi M, Chatterjee A. Curcumin exhibits antimetastatic properties by modulating integrin receptors, collagenase activity, and expression of Nm23 and Ecadherin. J Environ Pathol Toxicol Oncol 2003; 22: 49-58.
51. Tu C-T, Han B, Liu H-C, Zhang S-C. Curcumin protects mice against concanavalin A-induced hepatitis by inhibiting intrahepatic intercellular adhesion molecule-1 (ICAM-1) and CXCL10 expression. Mol Cell Biochem 2011; 358: 53-60.
52. Binion DG, Heidemann J, Li MS, Nelson VM, Rafiee P. Curcumin Selectively Inhibits VCAM-1 Expression in Human Intestinal Microvascular Endothelial Cells (HIMEC). Gastroenterology 2009; 136: A264-A.
53. Kumar A, Dhawan S, Hardegen NJ, Aggarwal BB. Curcumin (diferuloylmethane) inhibition of tumor necrosis factor (TNF)-mediated adhesion of monocytes to endothelial cells by suppression of cell surface expression of adhesion molecules and of nuclear factor-kappa B activation. Biochem Pharmacol 1998; 55: 775-83.
54. Zhang L, Gu Z-L, Qin Z-H, Liang Z-Q. Effect of curcumin on the adhesion of platelets to brain microvascular endothelial cells in vitro. Acta Pharmacol Sin 2008; 29: 800-7.
55. Kim HI, Huang H, Cheepala S, Huang S, Chung J. Curcumin inhibition of integrin (alpha6beta4)-dependent breast cancer cell motility and invasion. Cancer Prev Res (Phila) 2008; 1: 385-91.
56. Chen HW, Lee JY, Huang JY, et al. Curcumin inhibits lung cancer cell invasion and metastasis through the tumor suppressor HLJ1. Cancer Res 2008; 68: 7428-38.
57. Kim SR, Park HJ, Bae YH, et al. Curcumin down-regulates visfatin expression and inhibits breast cancer cell invasion. Endocrinology 2012; 153: 554-63.
58. Holy J. Curcumin inhibits cell motility and alters microfilament organization and function in prostate cancer cells. Cell Motil Cytoskeleton 2004; 58: 253-68.
59. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
60. Rafii S, Lyden D. Cancer. A few to flip the angiogenic switch. Science (New York, NY) 2008; 319: 163.
61. Du R, Lu KV, Petritsch C, et al. HIF1 alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 2008; 13: 206-20.
62. Semenza GL. HIF-1: using two hands to flip the angiogenic switch. Cancer Metastasis Rev 2000; 19: 59-65.
63. BAE MK, KIM SH, JEONG JW, et al. Curcumin inhibits hypoxiainduced angiogenesis via down-regulation of HIF-1. Oncol Rep 2006; 15: 1557-62.
64. Shih SC, Claffey KP. Role of AP-1 and HIF-1 transcription factors in TGF-β activation of VEGF expression. Growth Factors 2001; 19: 19-34.
65. Bachmeier BE, Nerlich AG, Iancu CM, et al. The chemopreventive polyphenol Curcumin prevents hematogenous breast cancer metastases in immunodeficient mice. Cell Physiol Biochem 2007; 19: 137-52.
66. El-Azab F, Hishe H, Moustafa Y, El-Awady E. Anti-angiogenic effect of resveratrol and curcumin through the inhibition of microvessel density, vegf and its receptor VEGFR-2 (flk-1) in ehrlich ascites carcinoma-bearing mice. Haematologica-the Hematology Journal 2010; 95: 352.
67. Han SY, Yang Y. Antimicrobial activity of wool fabric treated with curcumin. Dyes and Pigments 2005; 64: 157-61.
68. Ammayappan L, Moses JJ. Study of antimicrobial activity of aloevera, chitosan, and curcumin on cotton, wool, and rabbit hair. Fibers and Polymers 2009; 10: 161-6.
69. Koide T, Nose M, Ogihara Y, Yabu Y, Ohta N. Leishmanicidal effect of curcumin in vitro. Biol Pharm Bull 2002; 25: 131-3.
70. Chattopadhyay I, Biswas K, Bandyopadhyay U, Banerjee RK. Turmeric and curcumin: Biological actions and medicinal applications. Curr Sci 2004; 87: 44-53.
71. Rai D, Yadav D, Balzarini J, De Clercq E, Singh RK. Design and development of curcumin bioconjugates as antiviral agents. Nucleic Acids Symp Ser 2008; 52: 599-600.
72. Mishra S, Narain U, Mishra R, Misra K. Design, development and synthesis of mixed bioconjugates of piperic acid-glycine, curcumin-glycine/alanine and curcumin-glycine-piperic acid and their antibacterial and antifungal properties. Bioorg Med Chem 2005; 13: 1477-86.
73. Martins CVB, da Silva DL, Neres ATM, et al. Curcumin as a promising antifungal of clinical interest. J Antimicrob Chemother 2009; 63: 337-9.
74. Reddy RC, Vatsala PG, Keshamouni VG, Padmanaban G, Rangarajan PN. Curcumin for malaria therapy. Biochem Biophys Res Commun 2005; 326: 472-4.
75. Cheng AL, Hsu CH, Lin JK, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or premalignant lesions. Anticancer Res. 2001; 21: 2895-900.
76. Sharma RA, McLelland HR, Hill KA, et al. Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin Cancer Res 2001; 7: 1894-900.
77. Sharma RA, Euden SA, Platton SL, et al. Phase I clinical trial of oral curcumin. Clin Cancer Res 2004; 10: 6847-54.
78. Chandran B, Goel A. A randomized, pilot study to assess the efficacy and safety of curcumin in patients with active rheumatoid arthritis. Phytother Res 2012.
79. Lao CD, Ruffin MT, Normolle D, et al. Dose escalation of a curcuminoid formulation. BMC Complement Altern Med. 2006; 6: 10.
80. Garcea G, Jones D, Singh R, et al. Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration. Br J Cancer 2004; 90: 1011-5.
81. Garcea G, Berry DP, Jones DJL, et al. Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. Cancer Epidemiol Biomark Prev 2005; 14: 120-5.
82. Vareed SK, Kakarala M, Ruffin MT, et al. Pharmacokinetics of curcumin conjugate metabolites in healthy human subjects. Cancer Epidemiol Biomark Prev 2008; 17: 1411-7.
83. Lal B, Kapoor A, Asthana O, et al. Efficacy of curcumin in the management of chronic anterior uveitis. Phytother Res 1999; 13: 318-22.
84. Allegri P, Mastromarino A, Neri P. Management of chronic anterior uveitis relapses: efficacy of oral phospholipidic curcumin treatment. Long-term follow-up. Clin Ophthalmol 2010; 4: 1201-6.
85. Lal B, Kapoor A, Agrawal P, Asthana O, Srimal R. Role of curcumin in idiopathic inflammatory orbital pseudotumours. Phytother Res 2000; 14: 443-7.
86. Camilleri M. Dyspepsia, irritable bowel syndrome, and constipation: review and what's new. Rev Gastroenterol Disord 2001; 1: 2-17.
87. Bundy R, Walker AF, Middleton RW, Booth J. Turmeric extract may improve irritable bowel syndrome symptomology in otherwise healthy adults: a pilot study. J Altern Complem Med 2004; 10: 1015-8.
88. Prucksunand C, Indrasukhsri B, Leethochawalit M, Hungspreugs K. Phase II clinical trial on effect of the long turmeric (Curcuma longa Linn) on healing of peptic ulcer. Southeast Asian J Trop Med Public Health 2001; 32: 208-15.
89. Hanai H, Sugimoto K. Curcumin has bright prospects for the treatment of inflammatory bowel disease. Curr Pharm Des 2009; 15: 2087-94.
90. Taylor RA, Leonard MC. Curcumin for inflammatory bowel disease: a review of human studies. Altern Med Rev 2011; 16: 152-6.
91. Holt PR, Katz S, Kirshoff R. Curcumin therapy in inflammatory bowel disease: a pilot study. Dig Dis Sci 2005; 50: 2191-3.
92. Hanai H, Iida T, Takeuchi K, et al. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 2006; 4: 1502-6.
93. Durgaprasad S, Pai CG, Alvres JF, Namitha S. A pilot study of the antioxidant effect of curcumin in tropical pancreatitis. Indian J Med Res 2005; 122: 315-8.
94. Khanna D, Sethi G, Ahn KS, et al. Natural products as a gold mine for arthritis treatment. Curr Opin Pharmacol 2007; 7: 344-51.
95. Belcaro G, Cesarone M, Dugall M, et al. Product-evaluation registry of Meriva®, a curcumin-phosphatidylcholine complex, for the complementary management of osteoarthritis. Panminerva Med 2010; 52: 55-62.
96. Park C, Moon DO, Choi IW, et al. Curcumin induces apoptosis and inhibits prostaglandin E2 production in synovial fibroblasts of patients with rheumatoid arthritis. Int J Mol Med 2007; 20: 365-72.
97. Deodhar SD, Sethi R, Srimal RC. Preliminary study on antirheumatic activity of curcumin (diferuloyl methane). Indian J Med Res 1980; 71: 632-4.
98. Heng M, Song M, Harker J, Heng M. Drug-induced suppression of phosphorylase kinase activity correlates with resolution of psoriasis as assessed by clinical, histological and immunohistochemical parameters. Br J Dermatol 2000; 143: 937-49.
99. Kurd SK, Smith N, VanVoorhees A, et al. Oral curcumin in the treatment of moderate to severe psoriasis vulgaris: A prospective clinical trial. J Am Acad Dermatol 2008; 58: 625-31.
100. Brennan M. Endocrinology in cancer of the breast. Status and prospects. Am J Clin Pathol 1975; 64: 797.
101. Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 2005; 7: 211-8.
102. He ZY, Shi CB, Wen H, Li FL, Wang BL, Wang J. Upregulation of p53 expression in patients with colorectal cancer by administration of curcumin. Cancer Investig 2011; 29: 208-13.
103. Liu S, Wang Z, Hu Z, et al. Anti-tumor activity of curcumin against androgen-independent prostate cancer cells via inhibition of NFkappaB and AP-1 pathway in vitro. J Huazhong Univ Sci Technolog Med Sci 2011; 31: 530-4.
104. Liu HS, Ke CS, Cheng HC, Huang CYF, Su CL. Curcumin-induced mitotic spindle defect and cell cycle arrest in human bladder cancer cells occurs partly through inhibition of aurora A. Mol Pharmacol 2011; 80: 638-46.
105. Singh M, Singh N. Curcumin counteracts the proliferative effect of estradiol and induces apoptosis in cervical cancer cells. Mol Cell Biochem 2011; 347: 1-11.
106. Wu SH, Hang LW, Yang JS, et al. Curcumin induces apoptosis in human non-small cell lung cancer NCI-H460 cells through ER stress and caspase cascade-and mitochondria-dependent pathways. Anticancer Res 2010; 30: 2125-33.
107. Vasen HFA, Moeslein G, Alonso A, et al. Guidelines for the clinical management of familial adenomatous polyposis (FAP). Gut 2008; 57: 704-13.
108. Cruz-Correa M, Shoskes DA, Sanchez P, et al. Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis. Clin Gastroenterol Hepatol 2006; 4: 1035-8.
109. Golombick T, Diamond TH, Badmaev V, Manoharan A, Ramakrishna R. The potential role of curcumin in patients with monoclonal gammopathy of undefined significance-its effect on paraproteinemia and the urinary N-telopeptide of type I collagen bone turnover marker. Clin Cancer Res 2009; 15: 5917-22.
110. Carroll RE, Benya RV, Turgeon DK, et al. Phase IIa clinical trial of curcumin for the prevention of colorectal neoplasia. Cancer Prev Res 2011; 4: 354-64.
111. Braumann C, Guenther N, Loeffler LM, Dubiel W. Liver metastases after colonic carcinoma-palliative chemotherapy plus curcumin. Int J Colorectal Dis 2009; 24: 859-60.
112. Epelbaum R, Vizel B, Bar-Sela G. Phase II study of curcumin and gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2008; 26: 15619.
113. Kanai M, Yoshimura K, Asada M, et al. A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer. Cancer Chemother Pharmacol 2011; 68: 157-64.
114. Dhillon N, Aggarwal BB, Newman RA, et al. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 2008; 14: 4491-9.
115. Bayet-Robert M, Kwiatkowski F, Leheurteur M, et al. Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer. Cancer Biol Ther 2010; 9: 8-14.
116. Cole GM, Teter B, Frautschy SA. Neuroprotective effects of curcumin. The molecular targets and therapeutic uses of curcumin in health and disease 2007: 197-212.
117. Cole G, Yang F, Lim G, Cummings J, Masterman D, Frautschy S. A rationale for curcuminoids for the prevention or treatment of alzheimers disease. Curr Med Chem Immunol Endocr Metab Agents 2003; 3: 15-25.
118. Ringman JM, Frautschy SA, Cole GM, Masterman DL, Cummings JL. A potential role of the curry spice curcumin in Alzheimer's disease. Curr Alzheimer Res 2005; 2: 131-6.
119. Hutton M, Hardy J. The presenilins and Alzheimer's disease. Hum Mol Genet 1997; 6: 1639-46.
120. Fratiglioni L, De Ronchi D, Aguero TH. Worldwide prevalence and incidence of dementia. Drugs Aging 1999; 15: 365-75.
121. Mishra S, Palanivelu K. The effect of curcumin (turmeric) on Alzheimer's disease: An overview. Ann Indian Acad Neur 2008; 11: 13-9.
122. Mutsuga M, Chambers JK, Uchida K, et al. Binding of curcumin to senile plaques and cerebral amyloid angiopathy in the aged brain of various animals and to neurofibrillary tangles in alzheimer's brain. J Vet Med Sci 2011; 74: 51-7.
123. Goldgaber D, Lerman MI, McBride O, Saffiotti U, Gajdusek D. Characterization and chromosomal localization of a cDNA encoding brain amyloid of Alzheimer's disease. Science 1987; 235: 877-80.
124. Kang J, Lemaire HG, Unterbeck A, et al. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature (Lond) 1987; 325: 733-6.
125. Younkin SG. Evidence that A beta 42 is the real culprit in Alzheimer's disease. Ann Neurol 1995; 37: 287-8.
126. Selkoe DJ. Tanslating cell biology into therapeutic advances in Alzheimer's disease. Nature (Lond) 1999; 399: 23-31.
127. Iwata N, Tsubuki S, Takaki Y, et al. Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat Med 2000; 6: 143-50.
128. Puglielli L, Tanzi RE, Kovacs DM. Alzheimer's disease: the cholesterol connection. Nat Neurosci 2003; 6: 345-51.
129. Murray CA, Lynch MA. Evidence that increased hippocampal expression of the cytokine interleukin-1β is a common trigger for age-and stress-induced impairments in long-term potentiation. J Neurosci 1998; 18: 2974-81.
130. Lim GP, Chu T, Yang F, Beech W, Frautschy SA, Cole GM. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci 2001; 21: 8370-7.
131. Frautschy SA, Hu W, Kim P, et al. Phenolic anti-inflammatory antioxidant reversal of Abeta-induced cognitive deficits and neuropathology. Neurobiol Aging 2001; 22: 993-1005.
132. Sung S, Yao Y, Uryu K, et al. Early vitamin E supplementation in young but not aged mice reduces Abeta levels and amyloid deposition in a transgenic model of Alzheimer's disease. FASEB J 2004; 18: 323-5.
133. Fassbender K, Simons M, Bergmann C, et al. Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci USA 2001; 98: 5856-61.
134. Refolo LM, Pappolla MA, LaFrancois J, et al. A Cholesterol-Lowering Drug Reduces [beta]-Amyloid Pathology in a Transgenic Mouse Model of Alzheimer's Disease. Neurobiol Dis 2001; 8: 890-9.
135. Hsu HY, Wen MH. Lipopolysaccharide-mediated reactive oxygen species and signal transduction in the regulation of interleukin-1 gene expression. J Biol Chem 2002; 277: 22131-9.
136. Huang X, Atwood CS, Moir RD, Hartshorn MA, Tanzi RE, Bush AI. Trace metal contamination initiates the apparent auto-aggregation, amyloidosis, and oligomerization of Alzheimer's Abeta peptides. J Biol Inorg Chem 2004; 9: 954-60.
137. Ringman JM CG, Tend E, et al. Oral curcumin for the treatment of mild-to-moderate Alzheimer's disease: Tolerability and clinical and biomarker efficacy results of a placebo-controlled 24-week study. Proceedings of the Abstract of International Conference on Alzheimer's Disease Chicago, USA, July 26-31, 2008: T774.
138. Baum L, Lam CWK, Cheung SKK, et al. Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. J Clin Psychopharmacol 2008; 28: 110-3.
139. Beal MF. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? Ann Neurol 1992; 31: 119-30.
140. Schapira A, Cooper J, Dexter D, Clark J, Jenner P, Marsden C. Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem 1990; 54: 823-7.
141. Adams JJD, Chang ML, Klaidman L. Parkinsons Disease-redox mechanisms. Curr Med Chem 2001; 8: 809-14.
142. Sayre LM, Smith MA, Perry G. Chemistry and biochemistry of oxidative stress in neurodegenerative disease. Curr Med Chem 2001; 8: 721-38.
143. Chandra V, Pandav R, Dodge H, et al. Incidence of Alzheimer's disease in a rural community in India. Neurology 2001; 57: 985-9.
144. Lenaz G, Bovina C, Castelluccio C, et al. Mitochondrial complex I defects in aging. Mol Cell Biochem 1997; 174: 329-33.
145. Mythri RB, Jagatha B, Pradhan N, Andersen J, Bharath MMS. Mitochondrial complex I inhibition in Parkinson's disease: how can curcumin protect mitochondria? Antioxid Redox Signal 2007; 9: 399-408.
146. Lin TK, Hughes G, Muratovska A, et al. Specific modification of mitochondrial protein thiols in response to oxidative stress. J Biol Chem 2002; 277: 17048-56.
147. Jha N, Jurma O, Lalli G, et al. Glutathione depletion in PC12 results in selective inhibition of mitochondrial complex I activity. J Biol Chem 2000; 275: 26096-101.
148. Keeney PM, Xie J, Capaldi RA, Bennett Jr JP. Parkinson's disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled. J Neurosci 2006; 26: 5256-64.
149. Murray J, Taylor SW, Zhang B, Ghosh SS, Capaldi RA. Oxidative damage to mitochondrial complex I due to peroxynitrite. J Biol Chem 2003; 278: 37223-30.
150. Chan MMY, Huang HI, Fenton MR, Fong D. In vivo inhibition of nitric oxide synthase gene expression by curcumin, a cancer preventive natural product with anti-inflammatory properties. Biochem Pharmacol 1998; 55: 1955-62.
151. Bharath S, Hsu M, Kaur D, Rajagopalan S, Andersen JK. Glutathione, iron and Parkinson's disease. Biochem Pharmacol 2002; 64: 1037-48.
152. Vali S, Mythri R, Jagatha B, et al. Integrating glutathione metabolism and mitochondrial dysfunction with implications for Parkinson's disease: a dynamic model. Neuroscience 2007; 149: 917-30.
153. Jagatha B, Mythri RB, Vali S, Bharath M. Curcumin treatment alleviates the effects of glutathione depletion in vitro and in vivo: therapeutic implications for Parkinson's disease explained via in silico studies. Free Radic Biol Med 2008; 44: 907-17.
154. Selkoe DJ, Schenk D. Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. Annu Rev Pharmacol Toxicol 2003; 43: 545-84.
155. Giasson BI, Duda JE, Murray IV, et al. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 2000; 290: 985-9.
156. Takahashi T, Yamashita H, Nakamura T, Nagano Y, Nakamura S. Tyrosine 125 of [alpha]-synuclein plays a critical role for dimerization following nitrative stress. Brain Res 2002; 938: 73-80.
157. Ono K, Yamada M. Antioxidant compounds have potent anti-fibrillogenic and fibril-destabilizing effects for α-synuclein fibrils in vitro. J Neurochem 2006; 97: 105-15.
158. Ahmad B, Lapidus LJ. Curcumin prevents aggregation in α -synuclein by increasing the reconfiguration rate. J Biol Chem 2012; 287: 1-14.
159. Sacco RL AR, Albers G, Alberts MJ, Benavente O, Furie K, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Circulation 2006; 113: e409-49.
160. Olszanecki R, Jawien J, Gajda M, et al. Effect of curcumin on atherosclerosis in apoE/LDLR-double knockout mice. J Physiol Pharmacol 2005; 56: 627-35.
161. Strimpakos AS, Sharma RA. Curcumin: preventive and therapeutic properties in laboratory studies and clinical trials. Antioxid Redox Signal 2008; 10: 511-45.
162. Doroshow JH. Doxorubicin-induced cardiac toxicity. N Engl J Med 1991; 324: 843-5.
163. Wongcharoen W, Phrommintikul A. The protective role of curcumin in cardiovascular diseases. Int J Cardiol 2009; 133: 145-51.
164. Venkatesan N. Curcumin attenuation of acute adriamycin myocardial toxicity in rats. Br J Pharmacol 1998; 124: 425-7.
165. Backs J, Olson EN. Control of cardiac growth by histone acetylation/deacetylation. Circ Res 2006; 98: 15-24.
166. Clayton AL, Hazzalin CA, Mahadevan LC. Enhanced histone acetylation and transcription: a dynamic perspective. Mol Cell 2006; 23: 289-96.
167. Chan HM, La Thangue NB. p300/CBP proteins: HATs for transcriptional bridges and scaffolds. J Cell Sci 2001; 114: 2363-73.
168. Marcu MG, Jung YJ, Lee S, et al. Curcumin is an inhibitor of p300 histone acetylatransferase. Med Chem 2006; 2: 169-74.
169. Li HL, Liu C, de Couto G, et al. Curcumin prevents and reverses murine cardiac hypertrophy. J Clin Investig 2008; 118: 879.
170. Morimoto T, Sunagawa Y, Kawamura T, et al. The dietary compound curcumin inhibits p300 histone acetyltransferase activity and prevents heart failure in rats. J Clin Investig 2008; 118: 868-78.
171. Yeh CH, Chen TP, Wu YC, Lin YM, Jing Lin P. Inhibition of NFκB activation with curcumin attenuates plasma inflammatory cytokines surge and cardiomyocytic apoptosis following cardiac ischemia/reperfusion. J Surg Res 2005; 125: 109-16.
172. Ramirez BA, Soler A, Carrión-Gutiérrez MA, et al. An hydroalcoholic extract of Curcuma longa lowers the abnormally high values of human-plasma fibrinogen. Mech Ageing Dev 2000; 114: 207-10.
173. Alwi I, Santoso T, Suyono S, et al. The effect of curcumin on lipid level in patients with acute coronary syndrome. Acta Med Indones 2008; 40: 201-10.
174. Ceriello A, Taboga C, Tonutti L, et al. Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation. Circulation 2002; 106: 1211-8.
175. Farhangkhoee H, Khan ZA, Chen S, Chakrabarti S. Differential effects of curcumin on vasoactive factors in the diabetic rat heart. Nutr Metab (Lond) 2006; 3: 27.
176. Alderton WK, Cooper CE, Knowles RG. Nitric oxide synthases: structure, function and inhibition. Biochem J 2001; 357: 593-615.
177. Usharani P, Mateen A, Naidu M, Raju Y, Chandra N. Effect of NCB-02, atorvastatin and placebo on endothelial function, oxidative stress and inflammatory markers in patients with type 2 diabetes mellitus: a randomized, parallel-group, placebo-controlled, 8-week study. Drugs in R&D 2008; 9: 243-50.
178. Appendino G, Belcaro G, Cornelli U, et al. Potential role of curcumin phytosome (Meriva) in controlling the evolution of diabetic microangiopathy. A pilot study. Panminerva Med 2011; 53: 43-9.
179. Keane WF, Brenner BM, De Zeeuw D, et al. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. Kidney Int 2003; 63: 1499-507.
180. Rodrigo R, Rivera G. Renal damage mediated by oxidative stress: a hypothesis of protective effects of red wine. Free Radic Biol Med 2002; 33: 409-22.
181. Venkatesan N, Punithavathi D, Arumugam V. Curcumin prevents adriamycin nephrotoxicity in rats. Br J Pharmacol 2000; 129: 231-4.
182. Khajehdehi P, Pakfetrat M, Javidnia K, et al. Oral supplementation of turmeric attenuates proteinuria, transforming growth factor-beta and interleukin-8 levels in patients with overt type 2 diabetic nephropathy: a randomized, double-blind and placebo-controlled study. Scand J Urol Nephrol 2011; 45: 365-70.
183. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. Mol Pharm 2007; 4: 807-18.
184. Takahashi M, Uechi S, Takara K, Asikin Y, Wada K. Evaluation of an oral carrier system in rats: bioavailability and antioxidant properties of liposome-encapsulated curcumin. J Agric Food Chem 2009; 57: 9141-6.
185. Kurzrock R, Li L. Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. J Clin Oncol (Meeting Abstracts) 2005: 4091.
186. Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, Srinivas P. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med 1998; 64: 353-6.
187. Li L, Braiteh FS, Kurzrock R. Liposome-encapsulated curcumin. Cancer 2005; 104: 1322-31.
188. Li L, Ahmed B, Mehta K, Kurzrock R. Liposomal curcumin with and without oxaliplatin: effects on cell growth, apoptosis, and angiogenesis in colorectal cancer. Mol Cancer Ther 2007; 6: 1276.
189. Wang D, Veena MS, Stevenson K, et al. Liposome-encapsulated curcumin suppresses growth of head and neck squamous cell carcinoma in vitro and in xenografts through the inhibition of nuclear factor κB by an AKT-independent pathway. Clin Cancer Res 2008; 14: 6228-36.
190. Liu A, Lou H, Zhao L, Fan P. Validated LC/MS/MS assay for curcumin and tetrahydrocurcumin in rat plasma and application to pharmacokinetic study of phospholipid complex of curcumin. J Pharm Biomed Anal 2006; 40: 720-7.
191. Maiti K, Mukherjee K, Gantait A, Saha BP, Mukherjee PK. Curcumin-phospholipid complex: preparation, therapeutic evaluation and pharmacokinetic study in rats. Int J Pharm 2007; 330: 155-63.
192. Allegri P, Mastromarino A, Neri P. Management of chronic anterior uveitis relapses: efficacy of oral phospholipidic curcumin treatment. Long-term follow-up. Clinical Ophthalmology (Auckland, NZ) 2010; 4: 1201.
193. Belcaro G, Cesarone M, Dugall M, et al. Product-evaluation registry of Meriva®, a curcumin-phosphatidylcholine complex, for the complementary management of osteoarthritis. Panminerva Med 2010; 52: 55.
194. Belcaro G, Cesarone MR, Dugall M, et al. Efficacy and safety of Meriva®, a curcumin-phosphatidylcholine complex, during extended administration in osteoarthritis patients. Altern Med Rev 2010; 15: 337-44.
195. Cuomo J, Appendino G, Dern AS, et al. Comparative absorption of a standardized curcuminoid mixture and its lecithin formulation. J Nat Prod 2011; 74: 664-9.
196. Kanai M, Imaizumi A, Otsuka Y, et al. Dose-escalation and pharmacokinetic study of nanoparticle curcumin, a potential anticancer agent with improved bioavailability, in healthy human volunteers. Cancer Chemother Pharmacol 2012; 69: 65-70.
197. Wan S, Sun Y, Qi X, Tan F. Improved Bioavailability of Poorly Water-Soluble Drug Curcumin in Cellulose Acetate Solid Dispersion. AAPS PharmSciTech 2011; 13: 159-66.
198. Yan YD, Kim JA, Kwak MK, Yoo BK, Yong CS, Choi HG. Enhanced oral bioavailability of curcumin via a solid lipid-based selfemulsifying drug delivery system using a spray-drying technique. Biol Pharm Bull 2011; 34: 1179-86.
199. Xie X, Tao Q, Zou Y, et al. PLGA-nanoparticles Improves the Oral Bioavailability of Curcumin in Rats: Characterizations and Mechanisms. J Agric Food Chem 2011; 59: 9280-9.
200. Wu X, Xu J, Huang X, Wen C. Self-microemulsifying drug delivery system improves curcumin dissolution and bioavailability. Drug Dev Ind Pharm 2011; 37: 15-23.
201. Kakkar V, Singh S, Singla D, Kaur IP. Exploring solid lipid nanoparticles to enhance the oral bioavailability of curcumin. Mol Nutr Food Res 2011; 55: 495-503.
202. Ma Z, Haddadi A, Molavi O, Lavasanifar A, Lai R, Samuel J. Micelles of poly (ethylene oxide)-b-poly (ε-caprolactone) as vehicles for the solubilization, stabilization, and controlled delivery of curcumin. J Biomed Mater Res 2008; 86: 300-10.
203. Mohanty C, Acharya S, Mohanty AK, Dilnawaz F, Sahoo SK. Curcumin-encapsulated MePEG/PCL diblock copolymeric micelles: a novel controlled delivery vehicle for cancer therapy. Nanomedicine 2010; 5: 433-49.
204. Song Z, Feng R, Sun M, et al. Curcumin-loaded PLGA-PEG-PLGA triblock copolymeric micelles: Preparation, pharmacokinetics and distribution in vivo. J Colloid Interface Sci 2011; 354: 116-23.
205. Sasaki H, Sunagawa Y, Takahashi K, et al. Innovative preparation of curcumin for improved oral bioavailability. Biol Pharm Bull 2011; 34: 660-5.
206. Ryu EK, Choe YS, Lee KH, Choi Y, Kim BT. Curcumin and dehydrozingerone derivatives: synthesis, radiolabeling, and evaluation for β-amyloid plaque imaging. J Med Chem 2006; 49: 6111-9.
207. Cruz-Correa M, Shoskes DA, Sanchez P, et al. Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis. Clin Gastroenterol Hepatol 2006; 4: 1035-8.
208. Balasubramanian S, Eckert RL. Green tea polyphenol and curcumin inversely regulate human involucrin promoter activity via opposing effects on CCAAT/enhancer-binding protein function. Sci STKE 2004; 279: 24007-14.
209. Fang JY, Hung CF, Chiu HC, Wang JJ, Chan TF. Efficacy and irritancy of enhancers on the in-vitro and in-vivo percutaneous absorption of curcumin. J Pharm Pharmacol 2003; 55: 593-601.
210. Verma SP, Salamone E, Goldin B. Curcumin and genistein, plant natural products, show synergistic inhibitory effects on the growth of human breast cancer MCF-7 cells induced by estrogenic pesticides. Biochem Biophys Res Commun 1997; 233: 692-6.
211. Padhye S, Chavan D, Pandey S, Deshpande J, Swamy K, Sarkar F. Perspectives on chemopreventive and therapeutic potential of curcumin analogs in medicinal chemistry. Mini Rev Med Chem 2010; 10: 372-87.
212. Zhang X, Zhang H, Zhu G, et al. A novel mono-carbonyl analogue of curcumin induces apoptosis in ovarian carcinoma cells via endoplasmic reticulum stress and reactive oxygen species production. Mol Med Rep 2011; 5: 739-44.
213. Wang X, Zhang Y, Zhang X, Tian W, Feng W, Chen T. The curcumin analogue hydrazinocurcumin exhibits potent suppressive activity on carcinogenicity of breast cancer cells via STAT3 inhibition. Int J Oncol 2011; 40: 1189-95.
214. Bao B, Ali S, Banerjee S, et al. Curcumin Analogue CDF Inhibits Pancreatic Tumor Growth by Switching on Suppressor microRNAs and Attenuating EZH2 Expression. Cancer Res 2012; 72: 335-45.
215. Wang Y, Yu C, Pan Y, et al. A Novel Synthetic Mono-Carbonyl Analogue of Curcumin, A13, Exhibits Anti-Inflammatory Effects In vivo by Inhibition of Inflammatory Mediators. Inflammation 2011; 35: 594-604.
216. Wang Y, Xiao J, Zhou H, et al. A novel mono-carbonyl analogue of curcumin,(1E, 4E)-1, 5-bis (2, 3-dimethoxyphenyl) penta-1, 4-dien-3-one, induced cancer cell H460 apoptosis via activation of endoplasmic reticulum stress signaling pathway. J Med Chem 2011; 54: 3768-78.
217. Kunwar A, Barik A, Sandur SK, Indira Priyadarsini K. Differential antioxidant/pro-oxidant activity of dimethoxycurcumin, a synthetic analogue of curcumin. Free Radic Res 2011; 45: 959-65.
218. Patwardhan RS, Checker R, Sharma D, Kohli V, Priyadarsini K, Sandur SK. Dimethoxycurcumin, a metabolically stable analogue of curcumin, exhibits anti-inflammatory activities in murine and human lymphocytes. Biochem Pharmacol 2011; 82: 642-57.
219. Hutzen B, Friedman L, Sobo M, et al. Curcumin analogue GO-Y030 inhibits STAT3 activity and cell growth in breast and pancreatic carcinomas. Int J Oncol 2009; 35: 867-72.
220. Al-Hujaily EM, Mohamed AG, Al-Sharif I, et al. PAC, a novel curcumin analogue, has anti-breast cancer properties with higher efficiency on ER-negative cells. Breast Cancer Res Treat 2011; 128: 97-107.
221. XIAO J, CHU Y, HU K, et al. Synthesis and biological analysis of a new curcumin analogue for enhanced anti-tumor activity in HepG 2 cells. Oncol Rep 2010; 23: 1435-41.
222. Kalpana C, Sudheer A, Rajasekharan K, Menon V. Comparative effects of curcumin and its synthetic analogue on tissue lipid peroxidation and antioxidant status during nicotine-induced toxicity. Singapore Med J 2007; 48: 124-30.
223. Kamalakkannan N, Rukkumani R, Varma PS, Viswanathan P, Rajasekharan KN, Menon VP. Comparative Effects of Curcumin and an Analogue of Curcumin in Carbon Tetrachloride-induced Hepatotoxicity in Rats. Basic Clin Pharm Toxicol 2005; 97: 15-21.
224. Subramaniam D, May R, Sureban SM, et al. Diphenyl difluoroketone: a curcumin derivative with potent in vivo anticancer activity. Cancer Res 2008; 68: 1962-9.
225. Liu Y, Dargusch R, Maher P, Schubert D. A broadly neuroprotective derivative of curcumin. J Neurochem 2008; 105: 1336-45.
226. 2+/Calmodulin Function. Chem Biol 2004; 11: 1455-63.
227. Kumar AP, Garcia GE, Ghosh R, Rajnarayanan RV, Alworth WL, Slaga TJ. 4-hydroxy-3-methoxybenzoic acid methyl ester: A curcumin derivative targets Akt/NF kappa B cell survival signaling pathway: Potential for prostate cancer management. Neoplasia 2003; 5: 255-66.
228. Sup Shim J, Hoon Kim D, Jung HJ, et al. Hydrazinocurcumin, a novel synthetic curcumin derivative, is a potent inhibitor of endothelial cell proliferation. Bioorg Med Chem 2002; 10: 2439-44.
229. Kurien BT, Scofield RH. Heat-solubilized curcumin should be considered in clinical trials for increasing bioavailability. Clin Cancer Res 2009; 15: 747.
230. Bielak-Zmijewska A, Sikora-Polaczek M, Nieznanski K, et al. Curcumin disrupts meiotic and mitotic divisions via spindle impairment and inhibition of CDK1 activity. Cell Prolif 2010; 43: 354-64.
231. Sakano K, Kawanishi S. Metal-mediated DNA damage induced by curcumin in the presence of human cytochrome P450 isozymes. Arch Biochem Biophys 2002; 405: 223-30.
232. Chen Y, Liu WH, Chen BL, et al. Plant polyphenol curcumin significantly affects CYP1A2 and CYP2A6 activity in healthy, male Chinese volunteers. Ann Pharmacother 2010; 44: 1038-45.